Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome

Vittorio Pengo, Gentian Denas, Giacomo Zoppellaro, Seena Padayattil Jose, Ariela Hoxha, Amelia Ruffatti, Laura Andreoli, Angela Tincani, Caterina Cenci, Domenico Prisco, Tiziana Fierro, Paolo Gresele, Arturo Cafolla, Valeria De Micheli, Angelo Ghirarduzzi, Alberto Tosetto, Anna Falanga, Ida Martinelli, Sophie Testa, Doris Barcellona & 2 others Maria Gerosa, Alessandra Banzato

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid syndrome. This is a randomized open-label multicenter noninferiority study with blinded end point adjudication. Rivaroxaban, 20 mg once daily (15 mg once daily based on kidney function) was compared with warfarin (international normalized ratio target 2.5) for the prevention of thromboembolic events, major bleeding, and vascular death in patients with antiphospholipid syndrome. Only high-risk patients triple positive for lupus anticoagulant, anti-cardiolipin, and anti–b2-glycoprotein I antibodies of the same isotype (triple positivity) were included in the study. The trial was terminated prematurely after the enrollment of 120 patients (59 randomized to rivaroxaban and 61 to warfarin) because of an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. There were 11 (19%) events in the rivaroxaban group, and 2 (3%) events in the warfarin group. Thromboembolic events occurred in 7 (12%) patients randomized to rivaroxaban (4 ischemic stroke and 3 myocardial infarction), whereas no event was recorded in those randomized to warfarin. Major bleeding occurred in 6 patients: 4 (7%) in the rivaroxaban group and 2 (3%) in the warfarin group. No death was reported. The use of rivaroxaban in high-risk patients with antiphospholipid syndrome was associated with an increased rate of events compared with warfarin, thus showing no benefit and excess risk.

Original languageEnglish
Pages (from-to)1365-1371
Number of pages7
JournalBlood
Volume132
Issue number13
DOIs
Publication statusPublished - Sep 27 2018

Fingerprint

Antiphospholipid Syndrome
Warfarin
Hemorrhage
Rivaroxaban
Lupus Coagulation Inhibitor
Cardiolipins
International Normalized Ratio
Venous Thromboembolism
Atrial Fibrillation
Multicenter Studies
Blood Vessels
Labels
Glycoproteins
Stroke
Myocardial Infarction
Kidney
Safety
Antibodies

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Pengo, V., Denas, G., Zoppellaro, G., Jose, S. P., Hoxha, A., Ruffatti, A., ... Banzato, A. (2018). Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 132(13), 1365-1371. https://doi.org/10.1182/blood-2018-04-848333

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. / Pengo, Vittorio; Denas, Gentian; Zoppellaro, Giacomo; Jose, Seena Padayattil; Hoxha, Ariela; Ruffatti, Amelia; Andreoli, Laura; Tincani, Angela; Cenci, Caterina; Prisco, Domenico; Fierro, Tiziana; Gresele, Paolo; Cafolla, Arturo; De Micheli, Valeria; Ghirarduzzi, Angelo; Tosetto, Alberto; Falanga, Anna; Martinelli, Ida; Testa, Sophie; Barcellona, Doris; Gerosa, Maria; Banzato, Alessandra.

In: Blood, Vol. 132, No. 13, 27.09.2018, p. 1365-1371.

Research output: Contribution to journalArticle

Pengo, V, Denas, G, Zoppellaro, G, Jose, SP, Hoxha, A, Ruffatti, A, Andreoli, L, Tincani, A, Cenci, C, Prisco, D, Fierro, T, Gresele, P, Cafolla, A, De Micheli, V, Ghirarduzzi, A, Tosetto, A, Falanga, A, Martinelli, I, Testa, S, Barcellona, D, Gerosa, M & Banzato, A 2018, 'Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome', Blood, vol. 132, no. 13, pp. 1365-1371. https://doi.org/10.1182/blood-2018-04-848333
Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018 Sep 27;132(13):1365-1371. https://doi.org/10.1182/blood-2018-04-848333
Pengo, Vittorio ; Denas, Gentian ; Zoppellaro, Giacomo ; Jose, Seena Padayattil ; Hoxha, Ariela ; Ruffatti, Amelia ; Andreoli, Laura ; Tincani, Angela ; Cenci, Caterina ; Prisco, Domenico ; Fierro, Tiziana ; Gresele, Paolo ; Cafolla, Arturo ; De Micheli, Valeria ; Ghirarduzzi, Angelo ; Tosetto, Alberto ; Falanga, Anna ; Martinelli, Ida ; Testa, Sophie ; Barcellona, Doris ; Gerosa, Maria ; Banzato, Alessandra. / Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. In: Blood. 2018 ; Vol. 132, No. 13. pp. 1365-1371.
@article{a5b0fb16e22448419fde3037528c44d2,
title = "Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome",
abstract = "Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid syndrome. This is a randomized open-label multicenter noninferiority study with blinded end point adjudication. Rivaroxaban, 20 mg once daily (15 mg once daily based on kidney function) was compared with warfarin (international normalized ratio target 2.5) for the prevention of thromboembolic events, major bleeding, and vascular death in patients with antiphospholipid syndrome. Only high-risk patients triple positive for lupus anticoagulant, anti-cardiolipin, and anti–b2-glycoprotein I antibodies of the same isotype (triple positivity) were included in the study. The trial was terminated prematurely after the enrollment of 120 patients (59 randomized to rivaroxaban and 61 to warfarin) because of an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. There were 11 (19{\%}) events in the rivaroxaban group, and 2 (3{\%}) events in the warfarin group. Thromboembolic events occurred in 7 (12{\%}) patients randomized to rivaroxaban (4 ischemic stroke and 3 myocardial infarction), whereas no event was recorded in those randomized to warfarin. Major bleeding occurred in 6 patients: 4 (7{\%}) in the rivaroxaban group and 2 (3{\%}) in the warfarin group. No death was reported. The use of rivaroxaban in high-risk patients with antiphospholipid syndrome was associated with an increased rate of events compared with warfarin, thus showing no benefit and excess risk.",
author = "Vittorio Pengo and Gentian Denas and Giacomo Zoppellaro and Jose, {Seena Padayattil} and Ariela Hoxha and Amelia Ruffatti and Laura Andreoli and Angela Tincani and Caterina Cenci and Domenico Prisco and Tiziana Fierro and Paolo Gresele and Arturo Cafolla and {De Micheli}, Valeria and Angelo Ghirarduzzi and Alberto Tosetto and Anna Falanga and Ida Martinelli and Sophie Testa and Doris Barcellona and Maria Gerosa and Alessandra Banzato",
year = "2018",
month = "9",
day = "27",
doi = "10.1182/blood-2018-04-848333",
language = "English",
volume = "132",
pages = "1365--1371",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome

AU - Pengo, Vittorio

AU - Denas, Gentian

AU - Zoppellaro, Giacomo

AU - Jose, Seena Padayattil

AU - Hoxha, Ariela

AU - Ruffatti, Amelia

AU - Andreoli, Laura

AU - Tincani, Angela

AU - Cenci, Caterina

AU - Prisco, Domenico

AU - Fierro, Tiziana

AU - Gresele, Paolo

AU - Cafolla, Arturo

AU - De Micheli, Valeria

AU - Ghirarduzzi, Angelo

AU - Tosetto, Alberto

AU - Falanga, Anna

AU - Martinelli, Ida

AU - Testa, Sophie

AU - Barcellona, Doris

AU - Gerosa, Maria

AU - Banzato, Alessandra

PY - 2018/9/27

Y1 - 2018/9/27

N2 - Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid syndrome. This is a randomized open-label multicenter noninferiority study with blinded end point adjudication. Rivaroxaban, 20 mg once daily (15 mg once daily based on kidney function) was compared with warfarin (international normalized ratio target 2.5) for the prevention of thromboembolic events, major bleeding, and vascular death in patients with antiphospholipid syndrome. Only high-risk patients triple positive for lupus anticoagulant, anti-cardiolipin, and anti–b2-glycoprotein I antibodies of the same isotype (triple positivity) were included in the study. The trial was terminated prematurely after the enrollment of 120 patients (59 randomized to rivaroxaban and 61 to warfarin) because of an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. There were 11 (19%) events in the rivaroxaban group, and 2 (3%) events in the warfarin group. Thromboembolic events occurred in 7 (12%) patients randomized to rivaroxaban (4 ischemic stroke and 3 myocardial infarction), whereas no event was recorded in those randomized to warfarin. Major bleeding occurred in 6 patients: 4 (7%) in the rivaroxaban group and 2 (3%) in the warfarin group. No death was reported. The use of rivaroxaban in high-risk patients with antiphospholipid syndrome was associated with an increased rate of events compared with warfarin, thus showing no benefit and excess risk.

AB - Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid syndrome. This is a randomized open-label multicenter noninferiority study with blinded end point adjudication. Rivaroxaban, 20 mg once daily (15 mg once daily based on kidney function) was compared with warfarin (international normalized ratio target 2.5) for the prevention of thromboembolic events, major bleeding, and vascular death in patients with antiphospholipid syndrome. Only high-risk patients triple positive for lupus anticoagulant, anti-cardiolipin, and anti–b2-glycoprotein I antibodies of the same isotype (triple positivity) were included in the study. The trial was terminated prematurely after the enrollment of 120 patients (59 randomized to rivaroxaban and 61 to warfarin) because of an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. There were 11 (19%) events in the rivaroxaban group, and 2 (3%) events in the warfarin group. Thromboembolic events occurred in 7 (12%) patients randomized to rivaroxaban (4 ischemic stroke and 3 myocardial infarction), whereas no event was recorded in those randomized to warfarin. Major bleeding occurred in 6 patients: 4 (7%) in the rivaroxaban group and 2 (3%) in the warfarin group. No death was reported. The use of rivaroxaban in high-risk patients with antiphospholipid syndrome was associated with an increased rate of events compared with warfarin, thus showing no benefit and excess risk.

UR - http://www.scopus.com/inward/record.url?scp=85052248007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052248007&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-04-848333

DO - 10.1182/blood-2018-04-848333

M3 - Article

VL - 132

SP - 1365

EP - 1371

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -